Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study

Journal of Clinical Oncology

Volumn 21, Issue 5, 2003, Pages 843-850

  Therasse, P ^a   Mauriac, L ^a   Welnicka Jaskiewicz, M ^a   Bruning, P ^a   Cufer, T ^a   Bonnefoi, H ^a   Tomiak, E ^a   Pritchard, K I ^a   Hamilton, A ^a   Piccart, M J ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; FEC PROTOCOL;

ADJUVANT CHEMOTHERAPY; ANEMIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; BREAST TUMOR; COMPARATIVE STUDY; COST; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; ECONOMICS; MIDDLE AGED; PATHOLOGY; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FILGRASTIM; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037365648     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.135     Document Type: Article

References (33)

1. International Union Against Cancer (UICC): TNM-Classification of Malignant Tumors (ed 5). New York, Wiley-Liss, 1997
2. Zucali R, Uslenghi C, Kenda R, et al: Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer 37:1422-1431, 1976
3. Valero V, Buzdar A, Hortobagyi G: Locally advanced breast cancer. Oncologist 1:8-17, 1996
4. Rubens RD, Bartelink H, Engelsman E, et al: Locally advanced breast cancer: The contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Cooperative Group trial (10792). Eur J Cancer Clin Oncol 25:667-678, 1989
5. Bartelink H, Rubens RD, van der Schueren E, et al: Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European Organisation for Research and Treatment of Cancer randomised phase III trial. J Clin Oncol 15:207-215, 1997
6. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
7. Antman K, Corringham R, de Vries E, et al: Dose intensive therapy in breast cancer. Bone Marrow Transplant 10:67-73, 1992 (suppl 1)
8. Piccart M, Bruning P, Wildiers J, et al: An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer. Ann Oncol 6:673-677, 1995
9. Levine M, Bramwell V, Pritchard K, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16:2651-2658, 1998
10. Freedman LS, White SJ: On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 32:691-694, 1976
11. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1:121-129, 1982
12. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Analysis and examples. Br J Cancer 35:1-39, 1977
13. Kaplan E, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Cox DR: Regression models and life-tables. J R Stat Soc 34:187-202, 1972
15. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organisation for Research and Treatment of Cancer QLQ-C30: A Quality-of-life Instrument for Use in International Clinical Trials in Oncology. J Natl Cancer Inst 85:365-376, 1993
16. Curran D, Aaronson NK, Therasse P, et al: Summary measures and statistics in the analysis of quality of life data: An example from an EORTC-NCIC-SAKK locally advanced breast cancer study. Eur J Cancer 36:834-844, 2000
17. Biganzoli L, Piccart M: The bigger the better?... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol 8:1177-1182, 1997
18. Piccart M, Biganzoli L, Di Leo A: The impact of chemotherapy dose density and dose intensity on breast cancer outcome: What have we learned? Eur J Cancer 36:S4-S10, 2000 (suppl 1)
19. Cersosimo RJ, Hong WK: Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4:425-439, 1986
20. Fountzilas G, Athanassiades A, Giannakakis T, et al: A randomised study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 8:1213-1220, 1997
21. Arridzzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer. Br J Cancer 69:385-391, 1994
22. Del Mastro L, Venturini M, Lionetto R, et al: Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomised phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol 19:2213-2221, 2001
23. Venturini M, Del Mastro L: More on dose-intensity of anthracyclines in breast cancer. Ann Oncol 9:461, 1998
24. Sauerbrei W, Bastert G, Bojar H, et al: Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: An update based on 10 years' follow-up. German Breast Cancer Study Group. J Clin Oncol 18:94-101, 2000
25. Maass H: 3 versus 6 cycles of CMF in breast cancer patients with 1 to 9 positive nodes: Results of the German Adjuvant Breast Cancer (GQBQ) III trial. Proc Am Soc Clin Oncol 19:73a, 2000 (abstr 283)
26. International Breast Cancer Study Group: Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 14:1885-1894, 1995
27. Fumoleau P, Bremond A, Kerbral P, et al: Better outcome of premonopausal node-positive (N+) breast cancer patients (pts) treated with 6 cycles vs 3 cycles of adjuvant chemotherapy: Eight-year follow-up results of FASG 01. Proc Am Soc Clin Oncol 18:67a, 1999 (abstr 252)
28. Piccart M, Lohrisch C, Duchateau L, et al: Taxanes in the adjuvant treatment of breast cancer: Why not yet? J Natl Inst Monogr 30:88-95, 2001
29. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development conference statement: Adjuvant therapy for breast cancer, Nov 1-3,2000. J Natl Cancer Inst Monogr 30:5-15, 2001
30. Kuske RR: Diagnosis and management of inflammatory breast cancer. Semin Radiat Oncol 4:270-282, 1994
31. De Lena M, Varini M, Zucali R, et al: Multimodal treatment for locally advanced breast cancer: Results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 4:229-236, 1981
32. Olson JE, Neuberg D, Pandya KJ, et al: The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomised trial by the Eastern Cooperative Oncology Group. Cancer 79:1138-1149, 1997
33. Schwartz GF, Birchansky CA, Komarnicky LT, et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369, 1994